Where we at?, page-696

I recall Paul addressing the revert to 1.5mg twice weekly in a presentation Q and A somewhere. He suggests the 1.5 mg vs 2mg in Pharmakinetics, bioavailability and other preclinical work shows that the two drugs doses are comparable on certain aspects. In real life, this doesn’t play out this way…. Hence 008, biomarker data and therapeutic effect on MRI data and theurapeutic duration data.

005 008 SAS NFL had all been completed at 2mg. Given the adrenal FURPHY findings (and maybe other items in IND?) PAR responsibility is to prove 2mg is novel (above 1.5mg) and that it is their optimal/minimum effective dose.

I believe this is what they have set out to achieve since this time…..

But I’m not 100% on this…. this is my best guess